Research Article

The Relationship between the Transforming Growth Factor 1 T29C Gene Polymorphism and Left Ventricular Geometry and Function in Hypertensive Subjects

Table 1

Clinical characteristics and distribution of Leu10→Pro10 genotypes in hypertensives (Ht) with and without left ventricular hypertrophy (LVH).

Ht with LVHHt without LVH =

n.198235
Age50 ± 1049 ± 10.300
Gender (F/M)90/108124/111.590
BMI (Kg/m2)25 ± 624 ± 6.085
WHR0.86 ± 0.10.85 ± 0.1.300
SBP (mm/Hg)144 ± 15143 ± 16.505
DBP (mm/Hg)88 ± 987 ± 10.279
MBP (mm/Hg)106 ± 9 105 ± 9.250
Ht treated (%) 94.4% (187/198) 94.9% (223/235).987*
Diuretics 9% (17/187) 12.1% (27/223).394*
ACEi 58.8% (110/187) 61.8% (138/223).605*
ARB 42.8% (80/187) 40.3% (90/223).607*
CaCB 11.8% (22/187) 17.3% (30/223).199*
Duration of treatment (yrs)6.5 ± 3.3 6.2 ± 3.9.393
T29C (Leu10 Pro)
 TT15.1% (30/198)30.6% (72/235).0418
 TC64.7%* (128/198)49.8% (117/235).0434
 CC20.2%* (40/198)19.6% (46/235).0472
 TC + CC84.9%69.4%.0466

test.
F: Female; M: Male; BMI: Body mass index; WHR: Waist hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure;
MBP: mean blood pressure. ACEi: angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blockers; CaCB: calcium channel blockers. n.s. = not significant.